CVS Health (NYSE:CVS), a leading integrated healthcare and pharmacy solutions provider, released its fourth-quarter 2024 ...

Despite a recent 45% rally, I maintain a 'Sell' view on CVS due to its underwhelming execution record and rising leverage ...

Shareholders will be ecstatic, with their stake up 22% over the past week following CVS Health Corporation's (NYSE:CVS) ...

Equities researchers at Leerink Partnrs increased their Q1 2025 earnings estimates for shares of CVS Health in a research report issued on Wednesday, February 12th. Leerink Partnrs analyst M. Cherny ...

Sees FY25 free cash flow $6.5B. The company said, “The Company issued its full-year 2025 GAAP diluted EPS guidance range of $4.58 to $4.83 and ...

As healthcare spending continues to rise and regulatory pressure intensifies, companies like CVS Health CVS find themselves ...

CVS Health posted Q4 sales of $97.71B, with a 23.3% rise in Health Care Benefits revenue. Fiscal 2025 adjusted EPS guidance ...

Reports Q4 revenue $97.7B, consensus $96.88B. The company said, “Our integrated model allows us to uniquely deliver a simpler, connected ...

Adjusted EPS of $1.19 decreased from $2.12 in the prior year, beating the consensus of $0.93, primarily due to a decline in ...

CVS Health's adjusted EPS beat estimates at $1.19, surpassing the expected $0.91. Revenue increased to $97.7 billion, exceeding expectations and reflecting a growth of 4.2% year-over-year.

Looking ahead, CVS Health's management forecasts an adjusted EPS range of $5.75 to $6.00 for 2025, expecting enhancements in financial results as value-based initiatives and digital investments ...